Lords Mark Industries delivered a remarkable turnaround in the June 2026 quarter, posting a consolidated net profit of ₹33.18 crore compared to a net loss of ₹0.03 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a complete reversal from the company's financial position in June 2025, marking a significant operational improvement. The company has announced a strategic restructuring plan involving the demerger of its renewable energy and LED division into a separate entity, Lords Shakti Power Limited, with Lords Mark Industries retaining a 60% stake in the new entity. The scheme is expected to be filed by March 2027, allowing the energy business to pursue its capital programme independently while enabling the remaining healthcare and diagnostics businesses to be valued on their own fundamentals.
The company reported consolidated revenue of ₹307.68 crore in the quarter ended June 2026, as reported by Business Standard. However, there was a 37.3% quarter-on-quarter decline from the previous quarter's ₹491.17 crore. The standalone revenue also contracted 36.6% QoQ to ₹280.36 crore, down from ₹441.98 crore in Q4FY25. Looking ahead, the company has provided FY2027 guidance of ₹1,550 crore revenue and ₹178 crore PAT, with profit after tax (PAT) expected to grow over 50% and revenue projected to grow over 20% compared to FY26. Management expects consolidated revenue of at least ₹1,550 crore and PAT margin of 11.4%, representing a margin inflection of at least 200 basis points. The guidance indicates a divergence between top-line and bottom-line growth trajectories for FY27, with the acceleration in profitability suggesting operating leverage or improved cost structures in the core IVD and renewable energy segments.
Operating profit margin (OPM) was recorded at 15.98% for the quarter, according to the financial data reported by Business Standard. The company demonstrated exceptional cost discipline by reducing total expenses by 37.6% QoQ to ₹241.30 crore, contrasting sharply with the previous quarter's ₹388.28 crore. This cost management allowed the firm to achieve a profit before tax of ₹45.47 crore on the consolidated level, compared to a ₹0.03 crore loss in Q1FY25. The company's profit before depreciation and tax (PBDT) stood at ₹47.91 crore. The guidance indicates that the acceleration in profitability, alongside the margin expansion of at least 200 basis points to 11.4%, suggests the company anticipates operating leverage or improved cost structures in its core IVD and renewable energy segments, rather than pure volume-driven growth alone.
As of June 30, 2026, the standalone balance sheet showed total assets of ₹1,380.16 crore, an increase from ₹1,305.88 crore at the end of FY25. Current assets rose to ₹959.37 crore, driven largely by short-term loans and advances which jumped to ₹307.96 crore from ₹66.97 crore in March 2026. Trade receivables declined to ₹394.75 crore from ₹562.00 crore. Consolidated total assets stood at ₹1,491.55 crore, up from ₹1,443.02 crore. The consolidated accounts include four subsidiaries: Lords Mark Tech Next Private Limited, Lords Green Energy Private Limited, Renalyx Health Systems Private Limited, and Lords Mark Micro Biotech Private Limited. The company has outlined several strategic initiatives including CAR-T therapy partnerships, UK and Swiss subsidiaries, and new oncology hospitals. Management indicated that material contribution from the sickle cell testing business and the medical devices segment—comprising Onco Spectra and TB Truth—is expected from FY28 onward as these units commence meaningful commercialisation.
The proposed demerger will enable Lords Shakti Power Limited to enter the power transmission business through transformer manufacturing, expanding beyond its current renewable energy operations. The company has provided comprehensive guidance for FY27, projecting significant growth driven primarily by its base businesses of in vitro diagnostics (IVD) and renewable energy & LED. Management expects the material contribution from the sickle cell testing business and medical devices segment to commence from FY28 onward as these units commence meaningful commercialisation. The Board of Directors approved the unaudited financial results at its meeting held on August 13, 2026, with the results reviewed by the Audit Committee and limited reviewed by statutory auditors Sanjeev S Gupta & Associates. Additionally, the company has received a manufacturing license for Biomescan SaMD platform and is planning nationwide wellness centres, further expanding its healthcare capabilities. The company reported regulatory milestones for its diagnostic platforms, demonstrating progress in its healthcare delivery and diagnostics initiatives.
